SCHEMBL24409690

SCHEMBL24409690

CCCCNc1nc2cnc3cc(OCCO)ccc3c2n1CCO

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 2/20 0.40
PDE5A O76074 2/20 0.37
PDE6A P16499 2/20 0.37
PDE4A P27815 1/20 0.36
PDE4D Q08499 1/20 0.36
MAPT P10636 4/20 0.35
POLB P06746 1/20 0.35
TLR7 Q9NYK1 2/20 0.35
GAA P10253 1/20 0.35
TLR8 Q9NR97 1/20 0.35
CYP3A4 P08684 2/20 0.34
AXL P30530 1/20 0.34
FLT3 P36888 1/20 0.34
TYRO3 Q06418 1/20 0.34
MERTK Q12866 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
PDE4B Q07343 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24409692 0.86 CYP1A2 (0.38) SMN1; SMN2ALDH1A1PDE5APDE6AMAPT
SCHEMBL24409691 0.84 TLR7 (0.51) TLR7TLR8
SCHEMBL19968462 0.83 TLR7 (0.46) ALDH1A1PDE4APDE4DTLR7TLR8
SCHEMBL19968181 0.71 TLR7 (0.44) PDE4APDE4DTLR7TLR8PDE4B
SCHEMBL19968526 0.69 TLR7 (0.68) TLR7TLR8
SCHEMBL19968461 0.68 TLR7 (0.49) TLR7TLR8LMNA
SCHEMBL4246129 0.67 TLR7 (0.41) SMN1; SMN2TLR7GAALMNARAB9A
SCHEMBL22923016 0.66 TLR7 (0.53) TLR7TLR8
SCHEMBL5807920 0.65 TLR7 (0.43) SMN1; SMN2MAPTPOLBTLR7TLR8
SCHEMBL1486523 0.65 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1PDE4APDE4DMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220144833-A1 IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144833-A1 IMIDAZOQUINOLINE DERIVATIVES AND THEIR USE IN THERAPY MAVS, IRF3, MYD88 SMN1; SMN2 1753/4885ALDH1A1 3845/4885PDE5A 1989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.